Department of Thyroid Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, China.
Department of General Surgery, Zhongshan Hospital Xiamen University, Xiamen, 361004, China.
Eur J Surg Oncol. 2021 Jun;47(6):1346-1351. doi: 10.1016/j.ejso.2021.01.028. Epub 2021 Feb 2.
The transoral endoscopic thyroidectomy vestibular approach (TOETVA) has been increasingly used to treat patients with papillary thyroid cancer (PTC) with improved cosmetic outcomes. This study aimed to explore the safety and efficacy of TOETVA in patients with PTC.
This retrospective study included TOETVA patients from Yantai Yuhuangding and Xiamen Zhongshan Hospitals. Among the 297 patients studied, 84 had benign nodules (28.3%), 208 had PTC (70.0%), and five had follicular thyroid cancer (1.7%).
The incidence of transient and permanent recurrent laryngeal nerve injury was 1.3%, while that of transient hypoparathyroidism was 1.0%. Mental nerve paraesthesia was observed in 241 cases (81.1%), while permanent mental nerve paraesthesia was noted in seven cases (2.4%). Abnormal motor function of the lower lip and chin was observed in 12 cases (4.0%). Ten of the 208 patients with PTC (4.8%) underwent total thyroidectomy (TT) and bilateral central neck dissection (CND). A mean 6.6 ± 4.1 and 10.9 ± 4.0 lymph nodes were removed in the unilateral and bilateral surgeries, respectively, with a metastasis rate of 49.0%; a mean 2.7 ± 2.3 and 3.2 ± 2.6 lymph nodes were metastatic, respectively. The parathyroid gland was inadvertently removed in 6.6% and auto-transplanted in 10.6% of patients with unilateral PTC. The non-stimulated thyroglobulin level in the TT and bilateral CND patients was below 1 ng/mL at the 6-month follow-up.
TOETVA is safe in well-selected patients with unilateral PTC. However, its safety remains unclear in patients treated with TT and bilateral CND.
经口内镜甲状腺切除术前庭入路(TOETVA)已被越来越多地用于治疗甲状腺乳头状癌(PTC)患者,以获得更好的美容效果。本研究旨在探讨 TOETVA 治疗 PTC 患者的安全性和有效性。
本回顾性研究纳入了烟台毓璜顶医院和厦门中山医院的 TOETVA 患者。在研究的 297 名患者中,84 例为良性结节(28.3%),208 例为 PTC(70.0%),5 例为滤泡状甲状腺癌(1.7%)。
暂时性和永久性喉返神经损伤的发生率分别为 1.3%和 1.0%,暂时性甲状旁腺功能减退的发生率为 1.0%。241 例(81.1%)患者出现面神经感觉异常,7 例(2.4%)患者出现永久性面神经感觉异常。下唇和颏部运动功能异常 12 例(4.0%)。208 例 PTC 患者中,10 例行甲状腺全切除术(TT)和双侧中央颈部淋巴结清扫术(CND)。单侧和双侧手术分别切除平均 6.6±4.1 和 10.9±4.0 个淋巴结,转移率分别为 49.0%;平均 2.7±2.3 和 3.2±2.6 个淋巴结发生转移。单侧 PTC 患者中,甲状旁腺被无意中切除的比例为 6.6%,自动移植的比例为 10.6%。TT 和双侧 CND 患者在 6 个月随访时,非刺激甲状腺球蛋白水平均低于 1ng/mL。
TOETVA 用于治疗单侧 PTC 患者是安全的。然而,在接受 TT 和双侧 CND 治疗的患者中,其安全性仍不清楚。